Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients

Descriptive Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients - An Observational Retrospective Study

The study has descriptive purposes, with aim of assessing how turoctocog alfa is used in the everyday practice and to provide a baseline for the management of haemophilia A and does not involve any change in the clinical management of participants. Data will be extrapolated from the existing paper based medical records and uploaded to an electronic database specifically created for the study. Baseline information/history will be recorded at time of switching from previous FVIII replacement therapy to turoctocog alfa from the enrolled participants and outcomes will be collected according to participants visit format.

Inclusion Criteria:

• Paediatric and adult male patients
• On-demand and prophylactic patients with haemophilia A (any severity)
• Only previously treated patients (previous FVIII replacement therapy) will be included in the study

Exclusion Criteria:

• Patients diagnosed with coagulation disorders other than haemophilia A such as Von Willebrand disease
• Patients with documented presence of any FVIII inhibitor